Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Raises $40 Million in a Series C Financing
Toggle Summary Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
Fourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022 Full Year 2022 Factory Sales Expected to Increase Approximately 232% from Full Year 2021 Full Year 2023 Net Revenue Expected to be in Range of $25-$30 Million PRINCETON, N.J., Jan....
Toggle Summary Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in President...
Toggle Summary Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla ® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided...
Toggle Summary Agile Therapeutics President and Chief Executive Officer Al Altomari is an Ernst & Young Entrepreneur Of The Year® 2012 finalist in New Jersey
Toggle Summary Agile Therapeutics President and CEO appointed to Board of BioNJ
Toggle Summary Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017
Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational...
Toggle Summary Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes...
Toggle Summary Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needs Partnership represents first telehealth alliance for Agile’s Twirla ® birth control patch...
Toggle Summary Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
Partnership to focus on empowering women to take ownership of their health and healthcare options PRINCETON, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd ....
Shadow